Feature|Articles|April 17, 2024
- Pharmaceutical Executive: April 2024
- Volume 44
- Issue 4
Pharmaceutical Executive: April 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
Power in Partneringover 2 years ago
The IRA Impact: Navigating Its Evolving Complexitiesover 2 years ago
Fighting for Innovationover 2 years ago
Say Hello to Flexible: Reimagining the Patient Journeyover 2 years ago
Aspiring for the C-Suite? Consider Being a Chief of Staffover 2 years ago
Latent Benefit of Access Restrictions for Rare Conditionsover 2 years ago
The Pharmaceutical Playbook for Asia’s Private Marketover 2 years ago
Operating Models for Successful DOL EngagementAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
2026 Pharm Exec Top 50 Companies
2
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351
3
Who Pays for Tariff Driven Input Cost Increases?
4
Pharma’s New Growth Equation: Smarter Deals, Stronger Science, Rising Costs
5